Evidence map›Paper›PMID 31530590›Full record

ArticleBMJ open2019

Can clinical audits be enhanced by pathway simulation and machine learning? An example from the acute stroke pathway.

Michael Allen, Kerry Pearn, Thomas Monks, Benjamin D Bray, Richard Everson, Andrew Salmon, Martin James, Ken Stein

Abstract readComparative StudyMulticenter Study
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. A scoping review of patient and public involvement in empirical stroke research.International journal of stroke : official journal of the International Stroke Society · 2024
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michael AllenMedical School, University of Exeter, Exeter, UK M.Allen@exeter.ac.uk.
Kerry PearnMedical School, University of Exeter, Exeter, UK.
Thomas MonksUniversity of Southampton, Southampton, UK.
Benjamin D BrayPublic Health, Royal College Physicians, London, UK.
Richard EversonComputer Sciences, University of Exeter, Exeter, UK.
Andrew SalmonMedical School, University of Exeter, Exeter, UK.
Martin JamesStroke Consultant, Royal Devon & Exeter NHS Trust, Exeter, UK.
Ken SteinMedical School, University of Exeter, Exeter, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the application of clinical pathway simulation in machine learning, using clinical audit data, in order to identify key drivers for improving use and speed of thrombolysis at individual hospitals.

designComputer simulation modelling and machine learning.

settingSeven acute stroke units.

participantsAnonymised clinical audit data for 7864 patients.

resultsThree factors were pivotal in governing thrombolysis use: (1) the proportion of patients with a known stroke onset time (range 44%-73%), (2) pathway speed (for patients arriving within 4 hours of onset: per-hospital median arrival-to-scan ranged from 11 to 56 min; median scan-to-thrombolysis ranged from 21 to 44 min) and (3) predisposition to use thrombolysis (thrombolysis use ranged from 31% to 52% for patients with stroke scanned with 30 min left to administer thrombolysis). A pathway simulation model could predict the potential benefit of improving individual stages of the clinical pathway speed, whereas a machine learning model could predict the benefit of 'exporting' clinical decision making from one hospital to another, while allowing for differences in patient population between hospitals. By applying pathway simulation and machine learning together, we found a realistic ceiling of 15%-25% use of thrombolysis across different hospitals and, in the seven hospitals studied, a realistic opportunity to double the number of patients with no significant disability that may be attributed to thrombolysis.

conclusionsNational clinical audit may be enhanced by a combination of pathway simulation and machine learning, which best allows for an understanding of key levers for improvement in hyperacute stroke pathways, allowing for differences between local patient populations. These models, based on standard clinical audit data, may be applied at scale while providing results at individual hospital level. The models facilitate understanding of variation and levers for improvement in stroke pathways, and help set realistic targets tailored to local populations.

Indexed as

Machine LearningThrombolytic TherapyBrain IschemiaClinical AuditComputer SimulationEnglandFibrinolytic AgentsHospitalsHumansStrokeTime FactorsTime-to-TreatmentTissue Plasminogen ActivatorFibrinolytic AgentsTissue Plasminogen Activatoralteplasehealth services researchmachine learningsimulationStrokethrombolysis

Identifiers

PMID31530590
PMCPMC6756466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.